PDF(Pubmed)
Abstract：
Inflammatory bowel diseases (IBD), which include Crohn\'s disease and ulcerative colitis, manifest as a result of intricate interactions involving genetic predisposition, environmental factors, intestinal microbiota dynamics, and immune dysregulation, ultimately leading to persistent mucosal inflammation. Addressing this complex pathology requires a nuanced understanding to inform targeted therapeutic strategies. Consequently, our study explored the viability of Aged Garlic Extract (AGE) as an alternative therapeutic regimen for IBD management. Utilizing gas chromatography-mass spectrometry (GC-MS) and scanning electron microscopy (SEM), we characterized AGE, revealing distinctions from Fresh Garlic Extract (FGE), particularly the absence of allicin in AGE and accompanying structural alterations. In In-Vivo experiments employing an IBD rat model, AGE intervention exhibited remarkable antioxidant, antibacterial, and anti-inflammatory properties. Noteworthy outcomes included improved survival rates, mitigation of intestinal damage, restoration of gut microbial diversity, reinforcement of tight junctions, and reversal of mitochondrial dysfunction. Collectively, these effects contributed to the preservation of enterocyte integrity and the attenuation of inflammation. In conclusion, the unique chemical composition of AGE, coupled with its substantial influence on gut microbiota, antioxidant defenses, and inflammatory pathways, positions it as a promising adjunctive therapy for the management of IBD. These observations, synergistically considered with existing research, provide significant insights into the potential utility of AGE in addressing the intricate pathophysiology inherent to IBD. The potential strength of study and rationale of using AGE against IBD includes exploring alternative therapeutic regimens if conventional treatments are associated with side effects, identification of potential hotspots/pathways involved in disease progression and study can provide economically cheaper and naturally occurring alternative to patient community who are struggling to afford expensive medications. These promising findings underscore the necessity for additional investigations to ascertain the feasibility of clinical translation, thereby substantiating the potential therapeutic role of AGE in the management of IBD.
摘要：
炎症性肠病（IBD），其中包括克罗恩病和溃疡性结肠炎，表现为涉及遗传易感性的复杂相互作用的结果，环境因素,肠道微生物群动力学，和免疫失调，最终导致持续的粘膜炎症。解决这种复杂的病理需要细致入微的理解，以告知有针对性的治疗策略。因此,我们的研究探讨了老年大蒜提取物(AGE)作为IBD治疗替代方案的可行性.利用气相色谱-质谱(GC-MS)和扫描电镜(SEM),我们描述了年龄，揭示了新鲜大蒜提取物（FGE）的区别，特别是在AGE中不存在大蒜素和伴随的结构改变。在使用IBD大鼠模型的体内实验中，年龄干预表现出显著的抗氧化剂，抗菌，和抗炎特性。值得注意的结果包括提高生存率，缓解肠道损伤，肠道微生物多样性的恢复，加强紧密连接，和线粒体功能障碍的逆转。总的来说，这些作用有助于保持肠上皮细胞的完整性和减轻炎症。总之,AGE独特的化学成分，加上它对肠道微生物群的重大影响，抗氧化防御,和炎症途径，将其定位为IBD管理的有前途的辅助疗法。这些观察,与现有研究协同考虑，对AGE在解决IBD固有的复杂病理生理学方面的潜在效用提供了重要见解。研究的潜在强度和使用AGE治疗IBD的基本原理包括探索替代治疗方案，如果常规治疗与副作用相关，识别与疾病进展和研究有关的潜在热点/途径,可以为难以负担昂贵药物的患者群体提供经济上更便宜和自然发生的替代方案.这些有希望的发现强调了进行额外调查以确定临床翻译可行性的必要性。从而证实了AGE在IBD治疗中的潜在治疗作用。
